Saturday, May 11, 2024 2:43:26 PM
Dear TransCode Stockholder:
I am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TransCode Therapeutics, Inc (the “Company” or “TransCode”). The Annual Meeting will be held on June 13, 2024, at 9:30 a.m., local time, at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210.
We intend to hold our Annual Meeting in person. In the event it is not possible or advisable to hold our Annual Meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication. Please monitor our annual meeting website at https://ir.transcodetherapeutics.com/annual-meeting for updated information. If you are planning to attend our Annual Meeting, please check the website one week prior to the meeting date. To ensure that your vote is counted, we encourage you to vote your shares by proxy prior to the Annual Meeting. If you decide to change your vote or if you are a stockholder of record and decide to vote in person at the Annual Meeting, your updated vote will be the vote that is counted
Recent RNAZ News
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/20/2024 08:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:13:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 09:08:49 PM
- TransCode Therapeutics Open Letter to Shareholders • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 08:50:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:45:46 PM
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/15/2024 01:00:00 PM
- TransCode Therapeutics Reports 2023 Results; Provides Business Update • GlobeNewswire Inc. • 04/03/2024 01:10:00 PM
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment • GlobeNewswire Inc. • 03/11/2024 01:00:00 PM
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress • GlobeNewswire Inc. • 03/06/2024 09:15:00 PM
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:00:30 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:33:08 PM
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market • GlobeNewswire Inc. • 01/31/2024 09:05:00 PM
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:50 PM
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/22/2024 09:45:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/20/2024 02:57:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:08 AM
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 06:27:45 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:39:59 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/17/2024 12:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:22 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM